I looked up that company on the Nasdaq, and they lose $26 per share. o.O
I noticed 4 things:
1: [Poor general medical condition or any pathology that would limit the blood supply and compromise healing, as well as nonvascular surgical sites, should be considered when selecting patients for SkinTE™, as such conditions may compromise successful outcomes or lead to sub-optimal results.]
Non or slow healing wounds are most problematic in people with medical conditions that limit blood supply. Hence a real 'breakthrough' would be something that helps the patients WITH conditions that limit good wound healing.
2:[ If clinically successful, the PolarityTE™ platform will provide medical professionals with a truly new paradigm in wound healing and reconstructive surgery by utilizing a patient's own tissue substrates for the regeneration of skin, bone, muscle, cartilage, fat, blood vessels and nerves.]
With statement; 'IF clinically successful...', that seems to imply at this point in time, it has not demonstrated as such.
3:[But on December 1st of 2016, Lough and Swanson were catapulted instantaneously from coveted Plastic Surgery resident positions to the CEO and COO of Majesco Entertainment Co. (Nasdaq:COOL) in hopes that a merger between a 31-year-old failing gaming company and their own revolutionary technology would provide the field of medicine with the ability to regenerate new tissue — skin, bone, muscle, etc. Lough and Swanson are taking a huge gamble because the culture in the medical community is that you don’t leave to try a start-up and then come back if it doesn’t work. Indeed, in 92% of the last 100 life science start-ups to go public, the MD inventor of the flagship product didn’t work for the company....ref=
https://www.forbes.com/sites/innovatorsdna/2017/08/08/polarityte-will-this-biotech-be-the-next-amazon-or-tesla/#38b4ee40363a ]
WHAT?
merging a failing gaming ENTERTAINMENT company with medical technology???
4: [Institutions that own COOL; 'Cambridge Investment Advisors'] seem to own the MOST shares.
However, this 'Cambridge' is located somewhere near a corn field in Iowa and NOT where the cutting edge scientific institutions, (MIT, Harvard, MGH) with leaders in tissue regeneration.
I guess the OBVIOUS about this 'breakthrough' is the 'info' is written for the investor and not the scientist. IDK. Can't claim to have read in total everything about this 'breakthrough'. BUT it does look like they are using STEM CELLS which researchers already know will help in wound healing and regeneration.